Podcasts

Join Prof Iain McInnes in today’s podcast, where he will be reviewing two papers that investigate treatments for RA patients.

In the first paper, Philip Conaghan and colleagues evaluate the effectiveness in a Bruton’s tyrosine kinase inhibitor in treating rheumatoid arthritis in patients with an inadequate response to methotrexate.

In the second paper, Vincenzo Venerito and his team assessed the recombinant zoster vaccine in rheumatoid arthritis patients that are treated with JAK inhibitors.

Join Professors Peter Nash, Laura Coates, and Frank Behrens as they discuss the latest top research in PsA. The papers covered in this topical discussion highlight two fascinating therapeutics used in PsA treatment. This includes the latest evaluation of the efficacy and safety of guselkumab in DISCOVER-1 patients with active PsA by prior use of TNFi, as well as the latest investigation into the efficacy of secukinumab in patients with dactylitis at baseline over 2 years.

Dr Shikha Singla, Assistant Professor of Medicine at the Medical College of Wisconsin where she is also Medical Director of the psoriatic arthritis program. In this edition, Dr Singla discusses ehr latest paper 'Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study.'

Join Dr. Sofia Ramiro and Professor Hideto Kameda as they discuss the latest top research in axSpA. In this edition, our Steering Committee members discuss two of the latest papers in the field of axSpA therapeutics, providing their own insights and experience into two very interesting publications. The first of our publications discusses the incidence of MACEs in French patients newly benefiting from the French Long-term Illness scheme (LTI) for AS and to evaluate the effect of various treatments on the risk of MACE occurrence. Our second paper the goes on to evaluate the long-term safety profile for upadacitinib across RA, PsA, AS and AD.

Join Prof Iain McInnes as he reviews two interesting papers that help to broaden our understanding and knowledge on the safety of biologic and targeted synthetic DMARDs. In the first of today’s papers, Matthew Baker and colleagues determine the risk of developing interstitial lung disease (ILD) in patients with RA, undergoing treatment with different biologic and targeted synthetic DMARDs. In the second paper, Lars Kristensen and team analyse data from ORAL Surveillance to help identify subpopulations with different relative risk (i.e., ’high-risk’ and ’low-risk’) with tofacitinib versus TNFi.

Join Professors Iain McInnes, Laura Coates, and Peter Nash as they discuss the latest top research in PsA. The first paper we will discuss aimed to systematically review the incidence of HZ among RA, PsA, AS and UC patients treated with either TOFA, BARI or UPA. The second paper then goes on to describe the methodology being undertaken in the ground-breaking Phase 3b APEX study, which seeks to further assess the effects of guselkumab Q4W and Q8W on PsA outcomes.